DanielCostaMD

Thoracic Cancer

Physician

Dr. Costa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Yale-New Haven Medical Center (Primary Care)Residency, Internal Medicine, 2001 - 2004
Univ Sao Paulo- Fac MedClass of 2000

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer Start of enrollment: 2019 Jun 06
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Osimertinib In EGFR Mutant Lung Cancer Start of enrollment: 2018 Aug 13
Recruiting
Phase 2
Roles: Contact
Lorlatinib Combinations in Lung Cancer Start of enrollment: 2020 May 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact

PubMed

1101 citations
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski
Nature Communications. 2016-02-17
1447 citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw, Beow Y. Yeap, Mari Mino-Kenudson, Subba R. Digumarthy, Daniel B. Costa
Journal of Clinical Oncology. 2009-09-10
3454 citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon
The New England Journal of Medicine. 2010-10-28

2 Canadian Healthcare Stocks That Are All-Stars in the MakingSeptember 29th, 2021
2 Canadian Stocks to Buy That Could Double in 12 MonthsJune 25th, 2021
3 Top Canadian Growth Stocks to Buy Before They Take OffJune 24th, 2021